絞り込み

16645

広告

「"Cox TM "[Author]」の検索結果

248件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Comment: Why are females with Fabry disease affected?

Registered Nurses' Self-Assessed Knowledge of Evidence-Based Practice and Research: Moving Forward With New Information.

The lysosomal disease caused by mutant VPS33A.

Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

Splenic Artery Aneurysms, A Rare Complication of Type 1 Gaucher Disease: Report of Five Cases.

The lysosomal protein arylsulfatase B is a key enzyme involved in skeletal turnover.

The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series.

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

Genetics and Therapies for GM2 Gangliosidosis.

Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center.

Therapeutic position of eliglustat.

Reduced cerebral vascularisation in experimental neuronopathic Gaucher disease.

Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management.

Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.

Social Differentiation in Common Bottlenose Dolphins (Tursiops truncatus) that Engage in Human-Related Foraging Behaviors.

Brexit and rare diseases: big risk, bigger opportunity?

A specific activity-based probe to monitor family GH59 galactosylceramidase - the enzyme deficient in Krabbe disease.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
Sort by
※並べ替えは表示に時間がかかります